通讯作者: 李烨, 1301549503@qq.com

DOI：10.12201/bmr.202610.00064

A Case Report of FRα-Positive, Long-Duration, Multi-Line Recurrent Platinum-Resistant High-Grade Serous Ovarian Cancer Treated with Sacituzumab Govitecan

• 摘要：目的：探讨索米妥昔单抗在FRα阳性、长病程多线复发铂耐药高级别浆液性卵巢癌中的临床疗效、安全性及获得性耐药特征。方法：回顾分析1例经多线抗肿瘤治疗后反复复发、铂耐药且FRα表达阳性的高级别浆液性卵巢癌患者临床资料，患者予以索米妥昔单抗单药靶向治疗，规律随访，动态监测肿瘤标志物CA125、HE4及影像学变化，评估疗效与不良反应。结果：患者索米妥昔单抗治疗初期获益显著，CA125及HE4明显下降，影像学提示肿瘤病灶稳定，疾病得到有效控制，药物不良反应轻微且可耐受，但治疗后期患者出现获得性耐药，CA125及HE4持续升高。结论：索米妥昔单抗可使FRα阳性多线复发铂耐药高级别浆液性卵巢癌患者短期获益，安全性良好，但临床后期易出现耐药进展，需进一步明确耐药机制，探索联合治疗方案以期延缓耐药，为此类难治性卵巢癌精准治疗提供临床参考。

  关键词： 高级别浆液性卵巢癌；铂耐药复发；叶酸受体α；索米妥昔单抗；抗体药物偶联物; ; ; ; 

   

  Abstract: Objective: To explore the clinical efficacy, safety, and acquired resistance characteristics of sacituzumab govitecan in FRα-positive, long-course, multi-line refractory platinum-resistant high-grade serous ovarian cancer. Methods: A retrospective analysis was conducted on a patient with high-grade serous ovarian cancer who had recurrent disease after multiple lines of anti-tumor therapy, was platinum-resistant, and exhibited FRα-positive expression. The patient received monotherapy with sacituzumab govitecan, followed by regular follow-up, dynamic monitoring of tumor markers CA125 and HE4, and imaging changes to evaluate efficacy and adverse reactions. Results: The patient initially showed significant benefits from sacituzumab govitecan treatment, with notable decreases in CA125 and HE4 levels, and imaging indicated stable tumor lesions, effectively controlling the disease. The drug-related adverse reactions were mild and tolerable. However, in the later stages of treatment, the patient developed acquired resistance, with persistent increases in CA125 and HE4 levels. Conclusion: Sacituzumab govitecan can provide short-term benefits for FRα-positive, multi-line refractory platinum-resistant high-grade serous ovarian cancer patients, with favorable safety. However, resistance progression is prone to occur in the later clinical stages, necessitating further clarification of resistance mechanisms and exploration of combination treatment strategies to delay resistance, offering clinical reference for the precise treatment of this refractory ovarian cancer.

  Key words: Advanced-stage serous ovarian cancer; Platinum-resistant recurrence; Folate receptor alpha; Sacituzumab; Antibody-drug conjugate

  提交时间：2026-10-28

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 胡芷晴, 潘珊, 朱巍立. 铁死亡在逆转卵巢癌铂耐药中的研究进展. 2025. doi: 10.12201/bmr.202512.00070

  王良娇, 侯建峰, 廖华东, 陈洁平. 腹膜后淋巴结切除术在卵巢低级别浆液性癌中的应用现状和预后研究. 2026. doi: 10.12201/bmr.202610.00001

  袁阳珍, 李辉, 童柯轲. 复方皂角刺汤联合卡铂腹腔热灌注治疗卵巢癌恶性腹水（脾肾阳虚型）的临床观察. 2026. doi: 10.12201/bmr.202604.00092

  王子婕, 张鑫众. 叶酸受体阳性循环肿瘤细胞与非小细胞肺癌发生发展的研究进展. 2025. doi: 10.12201/bmr.202506.00024

  陶欣慧. 复发性卵巢癌患者自我调节疲劳现状及其与自我感受负担、社会支持的相关性分析. 2024. doi: 10.12201/bmr.202406.00033

  田梦娇, 张爱琴. 卵巢癌术后分型辨治经验. 2024. doi: 10.12201/bmr.202411.00016

  蔡小继, 车璇. 经阴道子宫切除术治疗绝经后非脱垂高级别宫颈病变的可行性和安全性. 2025. doi: 10.12201/bmr.202501.00068

  兰玲燕, 陈舒铃, 陈昀, 舒琦瑾. 基于数据挖掘探讨专利复方治疗卵巢癌用药规律. 2025. doi: 10.12201/bmr.202510.00008

  岳晓雪, 赵群. 年轻化疗耐药绒癌病例1例及文献复习. 2024. doi: 10.12201/bmr.202411.00007

  郑明康, 肖功亮, 吴强, 章庆华, 刘婷婷. 妊娠期结肠癌伴卵巢及肝肺转移1例并文献复习. 2026. doi: 10.12201/bmr.202610.00002

• 序号	提交日期	编号	操作
  1	2026-09-11	10.12201/bmr.202610.00064V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论